Biologics and respiratory complications: no overt PE risk with TK inhibitors
By Mardi Chapman
9 Apr 2019
Respiratory physicians asked for their take on the possible pulmonary side effects of small molecule tyrosine kinase inhibitors (TKIs) can reassure their colleagues. According to a meta-analysis of all published trial data on adverse events, there is some signal for infections but none for an increased risk of pulmonary embolism (PE). The findings are timely, ...